FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W655580100> ?p ?o ?g. }

• W655580100 endingPage "1123" @default.
• W655580100 startingPage "1123" @default.
• W655580100 abstract "1123 Background: While trastuzumab was approved in 1998 for treating patients with HER-2-positive MBC, there is little information on its use in the Medicare setting. Methods: We used SEER-Medicare data to examine patterns of trastuzumab use in women diagnosed with MBC . An index date was defined as either the date of diagnosis (stage IV) or of first distant recurrence (stage 0-III). Included patients were diagnosed in 2000–2002, and had their first claim for trastuzumab between their index date and December 31, 2005, the end of the observation period. Patients were divided into those who received trastuzumab as part of their first treatment following their index date (Group A), and those who began trastuzumab after at least one course of chemotherapy (Group B). Chemotherapy agents were grouped into antimicrotubule (vinorelbine, docetaxel, paclitaxel, vincristine), anthracycline (doxorubicin, epirubicin), cyclophosphamide, other, and unknown. Results: 281 patients met the inclusion criteria. Overall, the median (mean) time from the index date to initial chemotherapy and/or trastuzumab treatment was 35 (94) days (range 1–1,587 days). The average duration of trastuzumab use (first to last administration) was 371 days (median 239), during which patients averaged 2.3 trastuzumab claims per month. There were 192 (68%) patients in Group A. The median (mean) time from diagnosis to initial treatment in Group A was 34 (94) days. 64 (33%) received trastuzumab alone, and 121 (63%) received trastuzumab with an antimicrotubule. In Group B (89 patients), the median (mean) time to initial chemotherapy was 41 (92) days. 36 (40%) received anthracycline and/or cyclophosphamide based therapy, 22 (25%) received an antimicrotubule without either an anthracycline or cyclophosphamide. The median (mean) time from initial chemotherapy to initial trastuzumab therapy was 233 (368) days. At that time, 29 (33%) received trastuzumab alone, and 54 (61%) received trastuzumab plus an antimicrotubule. Conclusions: To our knowledge, this is the first study to describe patterns of trastuzumab use in Medicare. When used for metastatic breast cancer, trastuzumab was most often provided soon after diagnosis as part of initial treatment, and usually with an antimicrotubule agent. [Table: see text]" @default.
• W655580100 created "2016-06-24" @default.
• W655580100 creator A5000305488 @default.
• W655580100 creator A5018773741 @default.
• W655580100 creator A5021458679 @default.
• W655580100 creator A5032187510 @default.
• W655580100 creator A5072015843 @default.
• W655580100 creator A5087837152 @default.
• W655580100 date "2009-05-20" @default.
• W655580100 modified "2023-09-25" @default.
• W655580100 title "Trastuzumab use and CNS metastasis in Medicare patients diagnosed with metastatic breast cancer (MBC)" @default.
• W655580100 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.1123" @default.
• W655580100 hasPublicationYear "2009" @default.
• W655580100 type Work @default.
• W655580100 sameAs 655580100 @default.
• W655580100 citedByCount "0" @default.
• W655580100 crossrefType "journal-article" @default.
• W655580100 hasAuthorship W655580100A5000305488 @default.
• W655580100 hasAuthorship W655580100A5018773741 @default.
• W655580100 hasAuthorship W655580100A5021458679 @default.
• W655580100 hasAuthorship W655580100A5032187510 @default.
• W655580100 hasAuthorship W655580100A5072015843 @default.
• W655580100 hasAuthorship W655580100A5087837152 @default.
• W655580100 hasConcept C121608353 @default.
• W655580100 hasConcept C126322002 @default.
• W655580100 hasConcept C141071460 @default.
• W655580100 hasConcept C143998085 @default.
• W655580100 hasConcept C2775930923 @default.
• W655580100 hasConcept C2776694085 @default.
• W655580100 hasConcept C2776755627 @default.
• W655580100 hasConcept C2776802502 @default.
• W655580100 hasConcept C2778239845 @default.
• W655580100 hasConcept C2779786085 @default.
• W655580100 hasConcept C2780350996 @default.
• W655580100 hasConcept C2780835546 @default.
• W655580100 hasConcept C2781190966 @default.
• W655580100 hasConcept C530470458 @default.
• W655580100 hasConcept C71924100 @default.
• W655580100 hasConceptScore W655580100C121608353 @default.
• W655580100 hasConceptScore W655580100C126322002 @default.
• W655580100 hasConceptScore W655580100C141071460 @default.
• W655580100 hasConceptScore W655580100C143998085 @default.
• W655580100 hasConceptScore W655580100C2775930923 @default.
• W655580100 hasConceptScore W655580100C2776694085 @default.
• W655580100 hasConceptScore W655580100C2776755627 @default.
• W655580100 hasConceptScore W655580100C2776802502 @default.
• W655580100 hasConceptScore W655580100C2778239845 @default.
• W655580100 hasConceptScore W655580100C2779786085 @default.
• W655580100 hasConceptScore W655580100C2780350996 @default.
• W655580100 hasConceptScore W655580100C2780835546 @default.
• W655580100 hasConceptScore W655580100C2781190966 @default.
• W655580100 hasConceptScore W655580100C530470458 @default.
• W655580100 hasConceptScore W655580100C71924100 @default.
• W655580100 hasIssue "15_suppl" @default.
• W655580100 hasLocation W6555801001 @default.
• W655580100 hasOpenAccess W655580100 @default.
• W655580100 hasPrimaryLocation W6555801001 @default.
• W655580100 hasRelatedWork W1972536622 @default.
• W655580100 hasRelatedWork W2100230735 @default.
• W655580100 hasRelatedWork W2107960402 @default.
• W655580100 hasRelatedWork W2111633398 @default.
• W655580100 hasRelatedWork W2129950253 @default.
• W655580100 hasRelatedWork W2279715590 @default.
• W655580100 hasRelatedWork W2397990317 @default.
• W655580100 hasRelatedWork W2404781534 @default.
• W655580100 hasRelatedWork W4249932378 @default.
• W655580100 hasRelatedWork W655580100 @default.
• W655580100 hasVolume "27" @default.
• W655580100 isParatext "false" @default.
• W655580100 isRetracted "false" @default.
• W655580100 magId "655580100" @default.
• W655580100 workType "article" @default.